Combined pyridostigmine-thyrotrophin-releasing hormone test for the evaluation of hypothalamic somatostatinergic activity in healthy normal men. 
Pyridostigmine (PST), a cholinesterase inhibitor, induces a clear growth hormone (GH) release in man by suppression of hypothalamic somatostatin (SRIH).  Somatostatin suppresses thyrotrophin (TSH) release in rats and men.  Earlier studies showed that the thryotrophin-releasing hormone (TRH)-induced TSH response was not altered by 60-120 mg of PST.  We studied whether a larger dose (180 mg) of PST can increase the TSH response to TRH.  Six healthy young men were studied with the following six tests: (Test 1) 200 micrograms of TRH i.v.; ( Test 2) 180 mg of PST po; (Test 3) three different doses of PST (60, 120, 180 mg) + TRH; (Test 4) 100 micrograms of octreotide (SMS) i.v.; ( Test 5) SMS + TRH; (Test 6) PST + SMS + TRH.  A large dose of PST (180 mg) significantly augmented GH, TSH and prolactin responses to TRH, while smaller doses of PST (60 and 120 mg) did not significantly increase the responses of GH and TSH.  While the increased TRH-induced prolactin response by PST was not suppressed by SMS, the increased responses of GH and TSH were suppressed remarkably by SMS.  Most of the subjects noticed a mild to moderate abdominal pain, nausea and muscular fasciculation after the administration of a large dose of PST administration.  These data suggest that suppression of hypothalamic SRIH secretion by 180 mg of PST can augment the TSH response to TRH.  However, the considerable side effects should be minimized before clinical application of the combined PST-TRH test.